Biomerica Announces $2.23 Million Financing

• Financing priced at $1.60 with no warrants or discount
• B. Riley Principal Capital and B. Riley executives, as well as Biomerica's CEO and all members of Biomerica’s Board of Directors participated in the financing
• Proceeds expected to strengthen the Company's balance sheet and fund operations and support the Board's ongoing evaluation of potential strategic opportunities, including partnerships and business combinations

IRVINE, Calif., Aug. 27, 2026 — Biomerica, Inc. (Nasdaq: BMRA) (“Biomerica” or the “Company”), a developer and manufacturer of diagnostic test systems, today announced that it has entered into definitive agreements with institutional and individual investors for a private placement of 1,393,705 unregistered shares of the Company’s common stock at a price of $1.60 per share, expected to provide approximately $2.23 million in gross proceeds to the Company.

The financing was priced at $1.60 at the time the definitive agreements were entered into and includes no warrants or discounted securities.

Participation in the financing included B. Riley Principal Capital , certain executives and employees of B. Riley Securities, Inc. (“B. Riley”), the Company's Chief Executive Officer, and all members of the Company's Board of Directors, reflecting meaningful alignment between outside investors and Company leadership.

Following the closing of the financing, the Company expects to have approximately 4,588,968 shares of the Company’s common stock outstanding on a pro forma basis, with the shares issued in the financing representing approximately 30.4% of pro forma shares outstanding.

The Company intends to use the proceeds to strengthen its balance sheet and fund operations as its Board of Directors continues to evaluate a range of potential strategic opportunities intended to maximize shareholder value.

B. Riley Securities Engagement

Biomerica also announced that it has engaged B. Riley as its exclusive financial advisor in connection with the evaluation and potential pursuit of potential strategic opportunities.

Under the engagement, B. Riley may assist the Company in reviewing, evaluating and negotiating potential acquisitions, mergers, joint ventures, partnerships, spin-offs and other strategic combinations.

About Biomerica (NASDAQ: BMRA)

Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focuses on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development. The Company's Board of Directors continues to evaluate potential strategic opportunities with the goal of maximizing long-term shareholder value.

Corporate Contact

Zack Irani 949-645-2111 [email protected]

Source: Biomerica, Inc.